Sanofi India Q2 profit rises 20% as diabetes portfolio lifts margins
Sanofi India reported Q2 net profit of ₹83.5 crore, up 20.1% year on year, as its insulin portfolio grew 14%. Revenue rose 7.7% to ₹437.7 crore and EBITDA margin expanded to 26.3% from 23.4%, aided by higher public-sector business.
Sanofi India reported Q2 profit growth of 20% and margin expansion, led by 14% growth in its insulin portfolio. Public-sector revenue rose 70% as new Toujeo and Soliqua CARE Account wins expanded access to injectable diabetes therapies.
Why this matters
No related prior signals were supplied. Sanofi India’s Q2 results show margin expansion alongside insulin portfolio growth and increased public-sector business.
Retail-company signals are accelerating, up 204786% QoQ.